ALSO NOTED: Cephalon reports pain data; Sirna, GSK expand collaboration; and much more...

> Cephalon says a late-stage trial of its experimental tablet for "breakthrough" pain delivered supporting data on its effectiveness. The trial included 123 patients. Report [1]

> Sirna and GSK have added development programs for asthma and RSV as part of their collaboration deal. As part of the respiratory collaboration, the companies also plan to pursue RNAi-based therapeutics against chronic obstructive pulmonary disease (COPD) and allergic rhinitis. Release [2]

> Canada's Migenix has raised $8.8 million through the sale of a partial royalty interest. Release [3]

> A group of consumer advocates is taking the pharma industry to task for consistently overplaying drugs' effectiveness while sugarcoating any risks they present. Release [4]

> As a follow-up to the recent report on Dr. Alastair J.J. Wood's move to become general partner of Symphony Capital, here's a report on how Isis' deal with Symphony allowed it to avoid a licensing deal or merger. Article [5] (WSJ sub. req.)

> Sigma-Aldrich has acquired Iropharm's custom chemical synthesis facility in Ireland. Report [6]

> Adherex Technologies of Research Triangle Park, NC has raised $6.5 million in a private placement. Report [7]

> Qualyst has closed its second round of venture capital. Report [8]

And Finally… South Korean scientists have developed the world's second android, EveR-1, who has a vocabulary of 400 words and limited facial expressions. Article [9]